Acurx Pharmaceuticals stock (US00366D1037): Analyst consensus points to high upside from low Nasdaq base

Shares of Acurx Pharmaceuticals traded on the Nasdaq Capital Market under the ticker ACXP continue to change hands at low single-digit levels, with the last regular-session close reported at USD 1.98 on 05/29/2026, followed by USD 2.01 in after-hours trading, according to data cited by MarketBeat as of 05/29/2026.

The United States-based biotech, which is focused on anti-infective drug candidates, therefore remains far below its 52-week high of USD 21.00, and closer to the 52-week low of USD 1.33, highlighting the volatility investors in the U.S. small-cap biotech segment have faced over the past year.

On its home market in the United States, Acurx Pharmaceuticals is listed on Nasdaq, and the stock's market capitalization stood at roughly USD 8.51 million at the close on 05/29/2026, underscoring the company's micro-cap status in the U.S. equity universe.

The stock's latest closing level near USD 2.00 comes after a 1-for-20 reverse stock split that has already been implemented, an action referenced on Robinhood's corporate actions tracker for Acurx Pharmaceuticals.

Trading volume on 05/29/2026 reached 62,102 shares compared with an average volume of 108,550 shares, suggesting somewhat muted activity in the U.S. session relative to the typical turnover profile for this Nasdaq-listed name.

For investors in the German-speaking market who follow U.S. healthcare names via secondary trading venues, Acurx Pharmaceuticals is also available on German platforms such as Tradegate under its U.S. identifier, although liquidity there tends to be lower and prices are typically linked to the primary Nasdaq line.

The corporate website at Acurx Pharmaceuticals as of 06/01/2026 describes the company as a clinical-stage biopharmaceutical business headquartered in King of Prussia, Pennsylvania, emphasizing the focus on novel mechanisms to address antibiotic resistance.

The stock's current trading behavior reflects the broader sentiment toward early-stage biotech companies in the United States, where clinical and regulatory milestones, as well as funding conditions, often drive sharp repricing events over short periods.

The 52-week price span from USD 1.33 to USD 21.00, combined with the modest absolute market capitalization, underlines that Acurx Pharmaceuticals sits firmly in the high-risk segment of the U.S. biotech sector, where price swings can be pronounced in both directions around news flow or capital market actions.

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

Acurx Pharmaceuticals: core business model

Acurx Pharmaceuticals pursues a focused clinical-stage business model built around discovering and developing innovative antibiotic candidates that can be advanced through trials and then monetized via approvals, licensing deals or partnerships in infectious disease markets.

What banks and research houses say about Acurx Pharmaceuticals

According to MarketBeat as of 05/29/2026, two Wall Street research firms cover Acurx Pharmaceuticals, producing a consensus 12-month price target of USD 31.00 per share, which is materially above the closing price of USD 1.98 on Nasdaq on 05/29/2026.

MarketBeat data on 05/29/2026 indicates that among the two analysts, there is currently one buy rating and one sell rating, which together translate into an overall consensus rating of "Hold" for Acurx Pharmaceuticals, reflecting a divided view on the balance between the company's clinical potential and the risks embedded in its small-cap biotech profile.

The same MarketBeat analyst overview shows that both the high and low price targets are set at USD 31.00 for Acurx Pharmaceuticals as of 05/29/2026, underscoring that while coverage is limited, the target price level is consistent across the contributing firms.

Investors should note that analyst estimates for micro-cap biopharmaceutical companies such as Acurx Pharmaceuticals can shift quickly following clinical data releases, financing transactions or changes to development timelines, and that the consensus figure of USD 31.00 is based only on the small number of analysts identified.

Conclusion

Acurx Pharmaceuticals is trading on its home U.S. Nasdaq market at a level that positions the stock near the lower end of its 52-week band, with a micro-cap market value and a history of a 1-for-20 reverse stock split that contextualizes its recent price range.

The small number of Wall Street analysts covering the company assign a consensus "Hold" rating and a shared 12-month target of USD 31.00 as of 05/29/2026, a figure that stands markedly above the latest close and reflects the binary nature of expectations around its clinical-stage anti-infective portfolio.

For investors following United States biotech names, the stock's combination of low absolute price, modest market capitalization and concentrated analyst coverage underscores that future performance will likely hinge on tangible pipeline milestones, funding steps and regulatory interactions rather than on broad market factors alone.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.